

ABSTRACT OF THE DISCLOSURE

**[0048]** A therapeutic vaccine for the treatment of melanoma, mast cell tumors and sarcoma in mammals. The vaccine preferably comprises at least one allogenic cell line providing at least one, and preferably two or more gangliosides selected from the group consisting of GD-2, GD-3, GM-2, GM-3, GD-1b and GT-1b. At least one cytokine selected from the group consisting of GM-CSF, IL-2, IL-4, and IL-12 and at least one heat shock protein selected from the group consisting of HSP-60, HSP-70 and HSP-90 are added as adjuvants. A bacterial organism may further be added as an adjuvant.

T:\Client Documents\Minsh\001a\patapp092001MANcat2.wpd

PROPRIETARY INFORMATION